Eledon Pharmaceuticals, Inc.

Healthcare · Biotechnology · United States

Last price 2.77 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 225.32M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It uses its immunology expertise in targeting the CD40 Ligand (CD40L) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It is also developing its products for the prevention of allograft rejection in kidney tran...